PEAR 2: Pharmacogenomic Evaluation of Antihypertensive Responses 2
PEAR2 was a randomized clinical trial where a GWAS study was conducted in 457 hypertensive self-identified Caucasian and African American individuals who received metoprolol 100 mg and chlorthalidone 25 mg in a sequential monotherapy design. Data collected include home and clinic blood pressure, blood samples for testing for adverse metabolic effects and other biomarkers (glucose, insulin, total cholesterol, LDL, HDL, TG, uric acid, potassium, sodium, creatinine, plasma renin activity), RNA, and DNA and urine sample. The data will be used for replication of findings from the PEAR trial, along with new discoveries in order to define genetic determinants of antihypertensive response and adverse metabolic responses.
- Julie Johnson, University of Florida, Principal Investigator
- Eric Boerwinkle, The University of Texas Health Science Center
- Steve Turner, Mayo Clinic
- Rhonda Cooper-DeHoff, University of Florida
- Amber Beitelshees, University of Maryland
- Kent Bailey, Mayo Clinic
- Arlene Chapman, University of Chicago
- Yan Gong, University of Florida
- Yan Sun, Emory University
- Caitrin McDonough, University of Florida
- Zhiying Wang, The University of Texas Health Science Center
- Jorge Del Aguila, The University of Texas Health Science Center
- Jeffrey O’Connell, University of Maryland